OraSure Technologies, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Unless noted, financial amounts below are in millions of dollars. The company combined its Diagnostics and Molecular Solutions businesses into one reporting segment in February 2023.
Financial performance
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Net revenue | $85.4 | $80.2 | $240.4 | $147.9 |
| Gross profit | $26.4 | $27.8 | $92.2 | $52.1 |
| Gross margin | 31% | 35% | 38% | 35% |
| Operating income (loss) | $(6.4) | $(21.5) | $17.9 | $(37.6) |
| Net income (loss) | $(4.8) | $(18.6) | $22.4 | $(38.5) |
| Diluted EPS | $(0.07) | $(0.26) | $0.30 | $(0.53) |
- Q2 revenue increased 6%; COVID-19 Diagnostics revenue rose 10% to $47.5 million, and Diagnostics revenue, including HIV and HCV, grew 41% to $19.8 million. Molecular Products fell 26% to $13.1 million.
- First-half revenue grew 63%, principally on COVID-19 Diagnostics sales under U.S. government procurement contracts. COVID-19 Molecular Products fell 98% to $0.2 million as demand for PCR collection kits declined.
- Q2 gross margin contracted mainly because of $6.9 million of accelerated depreciation tied to the Thailand InteliSwab production wind-down and manufacturing transition. First-half margin nevertheless improved year over year, reflecting lower manufacturing inefficiencies, packaging and freight costs, and scrap expense.
- Operating expenses excluding impairment charges declined by $6.1 million in Q2 and $6.2 million in the first half, reflecting cost reductions and lower headcount. Q2 included $0.2 million of impairment charges versus $10.5 million in Q2 2022; first-half 2023 impairment charges were $1.3 million.
Cash, liquidity and obligations
- Cash and cash equivalents were $185.9 million at June 30, 2023, versus $84.0 million at year-end 2022; working capital was $295.1 million versus $256.1 million. The company held no short-term investments at June 30, compared with $26.9 million at year-end.
- Operating cash flow was positive $63.3 million for the first half, compared with cash use of $45.5 million in the prior-year period. Cash generation benefited from lower inventory and receivables, including collections on U.S. government InteliSwab shipments. Investing activities provided $38.2 million, including $17.8 million of government-contract funding; financing used $2.0 million.
- Total liabilities were $59.5 million, down from $79.8 million at December 31, 2022. The balance sheet reports lease liabilities, but no conventional borrowings are presented. Management expects existing cash to fund operating and capital needs for at least the next 12 months.
- $72.1 million, or 39% of cash, was held by the Canadian subsidiary. Further repatriation could have adverse tax consequences; the company intends to permanently reinvest historical undistributed foreign earnings.
Outlook, commentary and notable risks
- Management expects total net product and services revenue in the second half of 2023 to be below the first half, citing lower COVID-19 diagnostic demand. The filing provides no full-year revenue or earnings guidance.
- Under a $109 million U.S. government manufacturing-capacity contract, the company expected to collect the remaining approximately $30.9 million during the rest of 2023, subject to milestones; final validation testing was scheduled for late 2023.
- One non-commercial customer represented 56% of Q2 revenue and 70% of first-half revenue, creating significant customer concentration. It also accounted for 47% of accounts receivable at June 30.
- Manufacturing lines no longer expected to be used and certain research-lab improvements were impaired by $1.3 million in the first half. The company also executed workforce reductions, accruing $1.6 million of related costs at June 30.
- The company disclosed that its July 31 market value of $346.5 million was below carrying value; if the share price remains depressed or declines further, goodwill impairment may be required.
- OraSure appealed a court ruling of noninfringement in its patent dispute with Spectrum Solutions. Spectrum’s antitrust and inequitable-conduct counterclaims were withdrawn; patent review and sanctions motions remained pending.
- Other risks identified include reliance on sole-source suppliers, uncertainty in customer forecasts and demand, regulatory and quality requirements, and the company’s ability to sustain profitability and improve margins.
Important facts for investors to verify
- Whether second-half COVID-19 demand and government orders decline as management expects, and the resulting effect on revenue and margins.
- Timing and completion of DOD contract milestones, final manufacturing validation, and collection of remaining funding.
- Customer concentration, collections from the major non-commercial customer, and the trajectory of Molecular Products sales.
- Whether manufacturing transition costs, impairment exposure, or the goodwill risk lead to further charges.
- Cash availability and potential tax consequences of moving funds from Canada to the United States.